Inspire Report Results of Second Phase 3 Tiger-2 Trial with Denufosol for Cystic Fibrosis
M2 EquityBites › January 04, 2011
Linked as:
Summary
EQUITYBITES-(C)2011 M2 COMMUNICATIONS
Biopharmaceutical company Inspire Pharmaceuticals Inc (Nasdaq:ISPH) on Monday reported that its second Phase 3 clinical trial, TIGER-2, with denufosol tetrasodium for the treatment of cystic fibrosis (CF) did not achieve statistical significance for its primary efficacy endpoint.See the full content of this document
Extract
Inspire Report Results of Second Phase 3 Tiger-2 Trial with Denufosol for Cystic Fibrosis
The primary efficacy endpoint was change from baseline i...
See the full content of this document
Sponsored links
